Nat Med: A summary analysis of pathological response and survival rates of new complementary therapies for melanoma

Clinical outcomes in patients with metastasis melanoma have improved significantly over the past decade as a result of continuous improvement in systemic therapy.
in patients with stage IV melanoma, immunotherapy based on anti-PD-1 and BRAF/MEK combined target therapies had higher response rates and improved overall survival (OS).
current anti-PD-1 and BRAF/MEK treatment strategies have been approved for complementary treatment of Stage III melanoma patients.
treatments were significantly better than previous standards of care, the prognosis of stage III metastasis patients was still poor.
in clinical trials, the two-year recurrence rate was 40% for patients receiving assisted immunotherapy and 40% for patients receiving targeted assisted therapy.
, the researchers found that the true recurrence rate in 15-20 percent of patients was underestimated because they failed screening for early recurrence before starting complementary treatment.
THE pathologically-based RFS Kaplan-Meier curve analysis (full queue) Because of the small number of patients in various trials conducted to date, the relationship between the pathological response of new melanoma-assisted therapies and the patient's recurrence (RFS) and total survival (OS) is unclear.
the study, the researchers aggregated data from six clinical trials based on anti-PD-1 immunotherapy or BRAF/MEK targeted therapies.
the study included 192 cases in which 141 patients received immunotherapy (104, a combination of ipilimumab and navudium anti-nivolumab; 37 cases, anti-PD-1 monotherapy), while 51 patients received targeted therapy.
a pathologically based RFS phase Kaplan-Meier curve analysis (treatment queue) showed that 40% of patients achieved pathological complete remission (pCR): Targeted? Treatment was 47 per cent and immunotherapy was 33 per cent (43 per cent for combined treatment and 20 per cent for single-drug therapy).
pCR was associated with improvements in 2-year RFS (2-year RFS for pCR patients compared to 50% for pCR patients) and OS (95% for 2-year OS for pCR patients and 83% for pCR- patients).
researchers found that few patients who received pCR, near pCR, or partial remission of immunotherapy observed a recurrence of the disease (96 percent of patients with two years of RFS) and that no patients had died of melanoma so far.
2-year RFS for pCR patients who used targeted treatment was only 79% and OS was only 91%.
, the summary analysis revealed that the new assisted systemic therapy was highly active and had a high response rate and excellent patient RFS and OS periods.
the study showed a significant correlation between pathological response levels and patients' RFS and OS, the researchers suggest that this early endpoint could serve as an alternative indicator of melanoma development and patient survival in future clinical trials.